Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer

Product Name: Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer
CAS No.: 1262787-83-6
Chemical Name: Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer
Synonyms: Patritumab;U3-1287|||AMG-888;Patritumab (anti-ERBB3);Research Grade Patritumab;Research Grade Patritumab (DHD48404);Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer
CBNumber: CB75483111
Formula Weight: 0
MOL File: Mol file

More

Less

Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Chemical Properties,Usage,Production

Uses

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab.html" class="link-product" target="_blank">Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].

in vivo

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice^[1].
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo^[1].

Animal Model:	Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)^[1]
Dosage:	1 mg/body
Administration:	Intraperitoneal injection; twice a week for 4 weeks
Result:	Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line. Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.

References

[1] Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56. DOI:10.18632/oncotarget.2663

Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Suppliers

China 19 United States 2 Global 21

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

TargetMol Chemicals Inc.

Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Country: United States
ProdList: 32435
Advantage: 58

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

Shanghai Aladdin Biochemical Technology Co.,Ltd.

Tel: 400-6206333 13167063860
Email: anhua.mao@aladdin-e.com
Country: China
ProdList: 48457
Advantage: 58

1262787-83-6, Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimerRelated Search:

Tuvirumab Lusvertikimab Emerfetamab Modotuximab Vepalimomab reslizumab Rosmantuzumab Solitomab Sirtratumab Nacolomabtafenatox

Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer

Patritumab

Research Grade Patritumab (DHD48404)

Patritumab (anti-ERBB3)

U3-1287|||AMG-888

Research Grade Patritumab

1262787-83-6